Ibrance is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Ibrance is used in men and women to treat certain types of advanced breast cancer that has spread to other parts of the body. In postmenopausal women, Ibrance is given in combination with a hormonal medicine called letrozole (Femara). In others, it is given together with fulvestrant (Faslodex).
Ibrance dosing information. Usual adult dose for breast cancer: 28-day cycle: 125 mg orally once a day for 21 consecutive days followed by 7 days off treatment. Use: In combination with letrozole for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy.